阿斯利康攜重磅研究，創連續七年亮相美國臨床腫瘤學會(ASCO)全體大會紀錄，進一步彰顯重新定義乳腺癌治療和改變胃癌治療結局的雄心

阿斯利康

2025-05-22 16:54 9034

SERENA-6 研究的全體大會報告將聚焦用于晚期 HR 陽性乳腺癌一線治療的新一代口服 SERD 藥物 Camizestrant

MATTERHORN 研究的全體大會報告將展示英飛凡用于早期胃和胃食管結合部腺癌的圍手術期治療方案

DESTINY-Breast09 研究的專場口頭報告將強調優赫得在 HER2 陽性轉移性乳腺癌更前線治療的潛力

上海 2025年5月22日 /美通社/ -- 阿斯利康在2025年5月30日至6月3日召開的美國臨床腫瘤學會（ASCO）上，憑借行業領先的多樣化產品與管線布局的全新研究數據，進一步深化自身讓癌癥不再成為致死主因的雄心。

會上將有超過80個摘要公布，其中涵蓋20款已獲得批準的藥物和潛在新藥，包括兩項重磅研究的全體大會報告（plenary presentation），一項特別重磅研究摘要口頭報告（late-breaking oral abstract session），以及19項口頭報告。其中亮點包括：

SERENA-6 ：評估了Camizestrant與廣泛獲批的細胞周期蛋白依賴性激酶（CDK）4/6抑制劑聯合，用于一線治療激素受體（HR）陽性、HER2陰性且腫瘤出現ESR1突變的晚期乳腺癌患者的III期臨床研究（Plenary #LBA4）。Camizestrant是在研的新一代選擇性雌激素受體降解劑（SERD）和完全ER拮抗劑。這是首個在一線治療中取得陽性結果的新一代口服SERD藥物III期臨床研究，也是Camizestrant的首個III期陽性結果。
MATTERHORN：評估了度伐利尤單抗聯合FLOT化療作為可切除的早期和局部晚期的胃和胃食管結合部腺癌（GEJ）患者圍手術期治療方案的III期研究（Plenary #LBA5）。
DESTINY-Breast09：評估德曲妥珠單抗聯合帕妥珠單抗用于一線治療HER2陽性轉移性乳腺癌患者治療獲益的III期研究（口頭報告摘要#LBA1008）。
DESTINY-Gastric04 ：評估了德曲妥珠單抗用于二線治療HER2陽性不可切除和/或轉移性胃和胃食管結合部腺癌患者的治療獲益的III期研究（#LBA4002）。
NeoADAURA：奧希替尼聯合或不聯合化療作為新輔助治療用于可切除的早期EGFR突變非小細胞肺癌（NSCLC）的III期臨床研究（口頭報告摘要#8001）。
TROPION-Lung02：Datroway聯合帕博利珠單抗的聯合或不聯合鉑類一線化療治療無驅動基因突變的晚期非小細胞肺癌的Ib期臨床研究結果，基于計算病理學生物標志物分析（口頭報告摘要#8501）。
KOMET：評估司美替尼治療伴有癥狀性、無法手術的叢狀神經纖維瘤的1型神經纖維瘤病成人患者的III期臨床研究（快速口頭摘要#3014）。

阿斯利康全球執行副總裁、全球腫瘤研發負責人高書璨（ Susan Galbraith）表示："本次ASCO大會上公布的兩項乳腺癌重磅研究數據將凸顯我們在以創新藥物和產品管線改變腫瘤治療結局上所取得的進展。SERENA-6是首個采用循環腫瘤DNA檢測指導治療方案切換的一項關鍵III期臨床研究，開創了這一技術在一線治療中的應用，以延緩HR陽性、HER2陰性晚期乳腺癌的疾病進展。此外，DESTINY-Breast09研究評估了德曲妥珠單抗與帕妥珠單抗的聯合治療方案，這是十年來首次在HER2陽性轉移性乳腺癌廣泛患者群體中，證明療效優于目前一線治療標準方案的試驗。"

阿斯利康全球執行副總裁，全球腫瘤研發負責人Dave Fredrickson表示："MATTERHORN的研究數據證明，度伐利尤單抗作為胃和胃食管結合部腺癌患者圍手術期的治療方案，是我們將免疫療法遷入癌癥早期階段治療的成功例證，有望實現早期治愈的可能。這是阿斯利康連續第七年登上ASCO全體大會，這一非凡的里程碑彰顯出我們在多個癌腫領域已建立行業領先的腫瘤產品組合和強大的研發管線。

阿斯利康與第一三共聯合開發和商業化德曲妥珠單抗與Datroway；與默沙東（默沙東是美國新澤西州羅威市默克公司的公司商號）聯合開發和商業化司美替尼；與和黃醫藥合作開發和商業化賽沃替尼。

阿斯利康在 2025 年 ASCO 大會期間的重要演講 ¹

主要作者

摘要標題

演示文稿詳情 (CDT)

抗體偶聯藥物

Shitara, K

Trastuzumab deruxtecan (T-
DXd) vs ramucirumab (RAM) +
paclitaxel (PTX) in second-line
treatment of patients (pts) with
human epidermal growth factor
receptor 2-positive (HER2+)
unresectable/metastatic gastric
cancer (GC) or
gastroesophageal junction
adenocarcinoma (GEJA):
Primary analysis of the
randomized, phase 3
DESTINY-Gastric04 study.

Abstract #LBA4002

Oral Abstract Session

31 May 2025

3:24pm

Tolaney, SM

Trastuzumab deruxtecan (T-
DXd) + pertuzumab (P) vs
taxane + trastuzumab +
pertuzumab (THP) for first-line
(1L) treatment of patients (pts)
with human epidermal growth
factor receptor 2–positive
(HER2+) advanced/metastatic
breast cancer (a/mBC): Interim
results from DESTINY-Breast09.

Abstract #LBA1008

Oral Abstract Session

2 June 2025

7:30am

Dent, R

Exploratory biomarker analysis
of trastuzumab deruxtecan (T-
DXd) vs physician's choice of
chemotherapy (TPC) in HER2-
low/-ultralow, hormone
receptor-positive (HR+)
metastatic breast cancer (mBC)
in DESTINY-Breast06 (DB-06).

Abstract #1013

Oral Abstract Session

31 May 2025

3:23pm

Levy, BP

TROPION-Lung02:
Datopotamab deruxtecan
(Dato-DXd) plus
pembrolizumab (pembro) with
or without platinum
chemotherapy (Pt-CT) as first-
line (1L) therapy for advanced
non-small cell lung cancer (aNSCLC).

Abstract #8501

Oral Abstract Session

1 June 2025

8:12am

Waqar, SN

First-line (1L) datopotamab
deruxtecan (Dato-DXd) +
rilvegostomig in advanced or
metastatic non-small cell lung
cancer (a/mNSCLC): Results
from TROPION-Lung04 (cohort 5).

Abstract #8521

Poster Session

31 May 2025

1:30pm

腫瘤驅動因素和耐藥性

Turner, NC

Camizestrant + CDK4/6
inhibitor (CDK4/6i) for the
treatment of emergent ESR1
mutations during first-line (1L)
endocrine-based therapy (ET)
and ahead of disease
progression in patients (pts)
with HR+/HER2– advanced
breast cancer (ABC): Phase 3,
double-blind ctDNA-guided
SERENA-6 trial.

Abstract #LBA4

Plenary Session

1 June 2025

2:41pm

Lu, S

Savolitinib (Savo) combined
with osimertinib (osi) versus
chemotherapy (chemo) in
EGFR-mutant (EGFRm) and
MET-amplification (METamp)
advanced NSCLC after disease
progression (PD) on EGFR
tyrosine kinase inhibitor (TKI):
Results from a randomized
phase 3 SACHI study.

Abstract #LBA8505

Oral Abstract Session

1 June 2025

9:48am

Levy, BP

Efficacy and CNS results from
a randomized subset of the
phase 2 SAVANNAH study
comparing savolitinib (savo) +
osimertinib (osi) combination
with savo + placebo (PBO).

Abstract #8513

Rapid Oral Abstract Session

2 June 2025

8:06am

Chaft JE

Neoadjuvant (neoadj)
osimertinib (osi) ±
chemotherapy (CT) vs CT
alone in resectable (R)
epidermal growth factor
receptor-mutated (EGFRm)
NSCLC: NeoADAURA.

Abstract #8001

Oral Abstract Session

2 June 2025

3:12pm

免疫腫瘤學與雙特異性抗體

Janjigian, YY

Event-free survival in
MATTERHORN: a randomized,
phase 3 study of durvalumab
plus 5-fluorouracil, leucovorin,
oxaliplatin, and docetaxel
chemotherapy (FLOT) in
resectable
gastric/gastroesophageal
junction cancer (GC/GEJC).

Abstract #LBA5

Plenary Session

1 June 2025

3:13pm

Powles, T

Circulating tumor DNA (ctDNA)
in patients with muscle-invasive
bladder cancer (MIBC) who
received perioperative
durvalumab (D) in NIAGARA

Abstract #4503

Oral Abstract Session

1 June 2025

10:45am

Reck, M

Associations of post-surgical
MRD status with neoadjuvant
ctDNA dynamics, genomic
mutations, and clinical
outcomes in patients with
resectable NSCLC (R-NSCLC)
from the phase 3 AEGEAN trial.

Abstract #8009

Rapid Oral Abstract Session

1 June 2025

4:30pm

Barbie, DA

Clinical and molecular
characteristics of early
progressors (EPs) and long
-term progression-free survivors
(LTPs) from the phase 3
ADRIATIC trial of
consolidation durvalumab (D) vs placebo (P)
after concurrent
chemoradiotherapy (cCRT) in
limited-stage small-cell lung
cancer (LS-SCLC).

Abstract #8014

Rapid Oral Abstract Session

1 June 2025

5:12pm

Mayadev, J

Ultrasensitive detection and
tracking of circulating tumor
DNA (ctDNA) and association
with relapse and survival in
locally advanced cervical
cancer (LACC): Phase 3
CALLA trial analyses.

Abstract #5502

Oral Abstract Session

2 June 2025

8:48am

Westin, SN

Durvalumab plus
carboplatin/paclitaxel followed
by durvalumab with or without
olaparib as first-line treatment
for endometrial cancer:
Longitudinal changes in
circulating tumor DNA.

Abstract #5512

Rapid Oral Abstract Session

3 June 2025

8:30am

Erinjeri, JP

Outcomes by baseline tumor
burden using the 6-and-12
score in EMERALD-1: a phase
3 study of durvalumab (D) ±
bevacizumab (B) with transarterial
chemoembolization (TACE) in
embolization-eligible
unresectable hepatocellular
carcinoma (uHCC).

Abstract #4083
Poster Session

31 May 2025

9:00am

Cascone, T

Neoadjuvant durvalumab (D) +
chemotherapy (CT) + novel
anticancer agents and adjuvant
D ± novel agents in resectable
non-small-cell lung cancer
(NSCLC): Updated outcomes
from NeoCOAST-2.

Abstract #8046

Poster Session

31 May 2025

1:30pm

Zhou, J

First-line rilvegostomig (rilve)
plus chemotherapy (CTx) in
advanced biliary tract cancer
(BTC): Primary analysis of
GEMINI-Hepatobiliary substudy
2 Cohort A.

Abstract #4080

Poster Session

31 May 2025

9:00am

Xu, R

ARTEMIDE-Gastric01: a phase
3 randomized study of
rilvegostomig with
fluoropyrimidine and
trastuzumab deruxtecan (T-
DXd) as first-line (1L) treatment
for locally advanced or
metastatic HER2-positive
gastric or gastroesophageal
junction cancer (GC/GEJC).

Abstract #TPS4204

Poster Session

31 May 2025

9:00am

Mathias, C

ARTEMIDE-Lung03: a phase 3,
randomized, double-blind,
multicenter, global study of
rilvegostomig or
pembrolizumab in combination
with platinum-based
chemotherapy as first-line
treatment for patients with
metastatic non-squamous non-
small-cell lung cancer whose
tumors express PD-L1.

Abstract #TPS8653

Poster Session

31 May 2025

1:30pm

細胞療法

Yoo, C

RHEA-1: First-in-human (FIH)
study of AZD9793, a first-in-
class CD8-guided T cell-
engager (TCE) for glypican-3-
positive (GPC3+) advanced or
metastatic hepatocellular
carcinoma (HCC).

Abstract #TPS4215

Poster Session

31 May 2025

9:00am

Kim, TM

Safety and Efficacy of
AZD0486, a CD19xCD3 T-cell
Engager, in Relapsed or
Refractory Diffuse Large B-cell
Lymphoma.

Abstract #7046
Poster Session

1 June 2025

9:00am

Shadman, M

TITANium: An open-label,
global multicenter Phase 1/2
study of AZD5492, a first-in-
class subcutaneous CD8-
guided tri-specific T-cell
engager (TCE), in patients (pts)
with relapsed or refractory (r/r)
B-cell malignancies.

Abstract #TPS7091

Poster Session

1 June 2025

9:00am

Le Gouill, S

SOUNDTRACK-E: A Phase 1/2
Open-label Multicenter Study to
Evaluate the Safety and
Efficacy of AZD0486
Monotherapy or Combination
Therapy in Patients With
Mature B-cell Malignancies.

Abstract #TPS7083

Poster Session

1 June 2025

9:00am

罕見病藥物

Chen, AP

Efficacy and safety of
selumetinib in adults with
neurofibromatosis type 1 (NF1)
and symptomatic, inoperable
plexiform neurofibroma (PN):
Primary analysis of KOMET
(NCT04924608), a Phase 3,
international, randomized,
placebo-controlled study.

Abstract #3014

Rapid Oral Abstract Session

2 June 2025

8:00am

¹ 阿斯利康在2025年ASCO大會將公布超過80個摘要，涵蓋其產品和管線中的分子藥物

關于阿斯利康腫瘤領域的研究

阿斯利康正引領著腫瘤領域的一場革命，致力提供多元化的腫瘤治療方案，以科學探索腫瘤領域的復雜性，發現、研發并向患者提供改變生命的藥物。

阿斯利康專注于最具挑戰性的腫瘤疾病，通過持續不斷的創新，阿斯利康已經建立了行業領先的多元化的產品組合和管線，持續推動醫療實踐變革，改變患者體驗。

阿斯利康以期重新定義癌癥治療并在未來攻克癌癥。

關于阿斯利康

阿斯利康（LSE/STO/Nasdaq: AZN）是一家科學至上的全球生物制藥企業，專注于研發、生產及營銷處方類藥品，重點關注腫瘤、罕見病以及包括心血管腎臟及代謝、呼吸及免疫在內的生物制藥等領域。阿斯利康全球總部位于英國劍橋，業務遍布超過125個國家，創新藥物惠及全球數百萬患者。更多信息，請訪問www.astrazeneca.com。

關于阿斯利康中國

阿斯利康自1993年進入中國以來，專注中國患者需求最迫切的治療領域，包括腫瘤、心血管、腎臟、代謝、呼吸、消化、罕見病、疫苗抗體及自體免疫等，已將40多款創新藥物帶到中國。阿斯利康中國總部位于上海，并在上海和北京設立全球戰略研發中心，在北京、廣州、杭州、成都、青島設立區域總部，在無錫、泰州、青島建立全球生產供應基地，向全球70多個市場輸送優質創新藥品。

聲明：本文研究中涉及的多種藥品用法尚未在中國獲批適應癥，阿斯利康不推薦任何未被批準的藥品使用。

消息來源：阿斯利康

相關股票：

LSE:AZN NASDAQ:AZN